These terms and conditions govern your use of the website alphaminr.com and its related services.
These Terms and Conditions (“Terms”) are a binding contract between you and Alphaminr, (“Alphaminr”, “we”, “us” and “service”). You must agree to and accept the Terms. These Terms include the provisions in this document as well as those in the Privacy Policy. These terms may be modified at any time.
Your subscription will be on a month to month basis and automatically renew every month. You may terminate your subscription at any time through your account.
We will provide you with advance notice of any change in fees.
You represent that you are of legal age to form a binding contract. You are responsible for any
activity associated with your account. The account can be logged in at only one computer at a
time.
The Services are intended for your own individual use. You shall only use the Services in a
manner that complies with all laws. You may not use any automated software, spider or system to
scrape data from Alphaminr.
Alphaminr is not a financial advisor and does not provide financial advice of any kind. The service is provided “As is”. The materials and information accessible through the Service are solely for informational purposes. While we strive to provide good information and data, we make no guarantee or warranty as to its accuracy.
TO THE EXTENT PERMITTED BY APPLICABLE LAW, UNDER NO CIRCUMSTANCES SHALL ALPHAMINR BE LIABLE TO YOU FOR DAMAGES OF ANY KIND, INCLUDING DAMAGES FOR INVESTMENT LOSSES, LOSS OF DATA, OR ACCURACY OF DATA, OR FOR ANY AMOUNT, IN THE AGGREGATE, IN EXCESS OF THE GREATER OF (1) FIFTY DOLLARS OR (2) THE AMOUNTS PAID BY YOU TO ALPHAMINR IN THE SIX MONTH PERIOD PRECEDING THIS APPLICABLE CLAIM. SOME STATES DO NOT ALLOW THE EXCLUSION OR LIMITATION OF INCIDENTAL OR CONSEQUENTIAL OR CERTAIN OTHER DAMAGES, SO THE ABOVE LIMITATION AND EXCLUSIONS MAY NOT APPLY TO YOU.
If any provision of these Terms is found to be invalid under any applicable law, such provision shall not affect the validity or enforceability of the remaining provisions herein.
This privacy policy describes how we (“Alphaminr”) collect, use, share and protect your personal information when we provide our service (“Service”). This Privacy Policy explains how information is collected about you either directly or indirectly. By using our service, you acknowledge the terms of this Privacy Notice. If you do not agree to the terms of this Privacy Policy, please do not use our Service. You should contact us if you have questions about it. We may modify this Privacy Policy periodically.
When you register for our Service, we collect information from you such as your name, email address and credit card information.
Like many other websites we use “cookies”, which are small text files that are stored on your computer or other device that record your preferences and actions, including how you use the website. You can set your browser or device to refuse all cookies or to alert you when a cookie is being sent. If you delete your cookies, if you opt-out from cookies, some Services may not function properly. We collect information when you use our Service. This includes which pages you visit.
We use Google Analytics and we use Stripe for payment processing. We will not share the information we collect with third parties for promotional purposes. We may share personal information with law enforcement as required or permitted by law.
| QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
| TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
| (State or other jurisdiction of incorporation or organization) |
(I.R.S. Employer Identification Number) |
| |
||
(Address of principal executive offices) |
(Zip Code) |
| Title of each class registered |
Trading Symbol(s) |
Name of each exchange on which registered | ||
one-half of one redeemable warrant |
||||
the units |
||||
the units, each whole warrant exercisable for one Class A Ordinary Share at an exercise price of $11.50 |
| Large accelerated filer | ☐ | Accelerated filer | ☐ | |||
| ☒ | Smaller reporting company | |||||
| Emerging growth company | ||||||
Page No. |
||||||
| PART I. FINANCIAL INFORMATION |
||||||
| Item 1. |
1 |
|||||
1 |
||||||
2 |
||||||
3 |
||||||
4 |
||||||
5 |
||||||
| Item 2. |
20 |
|||||
| Item 3. |
22 |
|||||
| Item 4. |
22 |
|||||
| PART II. OTHER INFORMATION |
||||||
| Item 1. |
24 |
|||||
| Item 1A. |
24 |
|||||
| Item 2. |
24 |
|||||
| Item 3. |
24 |
|||||
| Item 4. |
24 |
|||||
| Item 5. |
24 |
|||||
| Item 6. |
25 |
|||||
26 |
||||||
• |
our ability to select an appropriate target business or businesses; |
• |
our ability to complete our initial business combination; |
• |
our expectations around the performance of the prospective target business or businesses; |
• |
our success in retaining or recruiting, or changes required in, our officers, key employees or directors following our initial business combination; |
• |
our officers and directors allocating their time to other businesses and potentially having conflicts of interest with our business or in approving our initial business combination; |
• |
our potential ability to obtain additional financing to complete our initial business combination; |
• |
our pool of prospective target businesses; |
• |
our ability to consummate an initial business combination due to the uncertainty resulting from the COVID-19 pandemic and other events (such as an outbreak or escalation of armed hostilities or acts of war, terrorist attacks, natural disasters or other significant outbreaks of infectious diseases); |
• |
the ability of our officers and directors to generate a number of potential business combination opportunities; |
• |
our public securities’ potential liquidity and trading; |
• |
the lack of a market for our securities; |
• |
the use of proceeds not held in the trust account or available to us from interest income on the trust account balance; |
• |
the trust account not being subject to claims of third parties; or |
• |
our financial performance following our initial public offering. |
March 31, 2022 |
December 31, 2021 |
|||||||
(Unaudited) |
||||||||
| ASSETS |
||||||||
| Current assets: |
||||||||
| Cash |
$ | $ | ||||||
| Prepaid expenses |
||||||||
| |
|
|
|
|||||
| Total current assets |
||||||||
| Investments held in Trust Account |
||||||||
| |
|
|
|
|||||
| TOTAL ASSETS |
$ |
$ |
||||||
| |
|
|
|
|||||
| LIABILITIES AND SHAREHOLDERS’ DEFICIT |
||||||||
| Current liabilities: |
||||||||
| Accounts payable |
$ | $ | ||||||
| Accrued offering costs |
||||||||
| Due to Sponsor |
||||||||
| Accrued expenses |
||||||||
| Accrued expenses - related party |
||||||||
| |
|
|
|
|||||
| Total current liabilities |
||||||||
| Deferred underwriting fee payable |
||||||||
| |
|
|
|
|||||
| Total liabilities |
||||||||
| Commitments and Contingencies (Note 6) |
||||||||
| Class A ordinary shares subject to possible redemption, and shares at redemption value of $ at March 31, 2022 and December 31, 2021, respectivel y |
|
|||||||
| Shareholders’ Deficit |
||||||||
| Preference shares, $ |
||||||||
| Class A ordinary shares, $ e xcluding |
||||||||
| Class B ordinary shares, $ at March 31, 2022 and December 31, 2021, respectively (1) |
||||||||
| Additional paid-in capital |
||||||||
| Accumulated deficit |
( |
) | ( |
) | ||||
| |
|
|
|
|||||
| Total Shareholders’ Deficit |
( |
) |
( |
) | ||||
| |
|
|
|
|||||
| TOTAL LIABILITIES AND SHAREHOLDERS’ DEFICIT |
$ |
$ |
||||||
| |
|
|
|
|||||
(1) |
Includes up to |
Three Months Ended March 31, 2022 |
For the Period From February 3, 2021 (Inception) Through March 31, 2021 |
|||||||
| Formation and operating costs |
$ | $ | ||||||
| |
|
|
|
|||||
| Loss from operations |
( |
) |
( |
) | ||||
| Loss on sale of Private Placement Warrants |
( |
) | — | |||||
| Gain on investments held in Trust Account |
— | |||||||
| |
|
|
|
|||||
| Net loss |
$ |
( |
) |
$ |
( |
) | ||
| |
|
|
|
|||||
| Basic and diluted weighted average shares outstanding, Class A ordinary shares |
— | |||||||
| |
|
|
|
|||||
| Basic and diluted net loss per share, Class A ordinary shares |
$ | ( |
) | $ | — | |||
| |
|
|
|
|||||
| Basic and diluted weighted average shares outstanding, Class B ordinary shares |
||||||||
| |
|
|
|
|||||
| Basic and diluted net loss per share, Class B ordinary shares |
$ | ( |
) | $ | ( |
) | ||
| |
|
|
|
|||||
Class A Ordinary Shares |
Class B Ordinary Shares |
Additional Paid-in Capital |
Accumulated Deficit |
Total Shareholders’ Deficit |
||||||||||||||||||||||||
Shares |
Amount |
Shares |
Amount |
|||||||||||||||||||||||||
| Balance at December 31, 2021 |
$ |
$ |
$ |
$ |
( |
) |
$ |
( |
) | |||||||||||||||||||
| Proceeds from Initial Public Offering allocated to Public Warrants, net of offering costs |
— | — | — | — | — | |||||||||||||||||||||||
| Issuance of Private Placement Warrants |
— | — | — | — | — | |||||||||||||||||||||||
| Forfeiture of Class B Shares by Sponsor |
— | — | ( |
) | ( |
) | — | — | ||||||||||||||||||||
| Accretion of Class A ordinary shares to redemption amount |
— | — | — | — | ( |
) | ( |
) | ( |
) | ||||||||||||||||||
| Net loss |
— | — | — | — | — | ( |
) | ( |
) | |||||||||||||||||||
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||
| Balance at March 31, 2022 |
$ |
$ |
$ |
$ |
( |
) |
$ |
( |
) | |||||||||||||||||||
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||
Class A Ordinary Shares |
Class B Ordinary Shares |
Additional Paid-in Capital |
Accumulated Deficit |
Total Shareholder’s Equity |
||||||||||||||||||||||||
Shares |
Amount |
Shares |
Amount |
|||||||||||||||||||||||||
| Balance at February 3, 2021 (inception) |
$ |
$ |
$ |
$ |
$ |
|||||||||||||||||||||||
| Issuance of Class B ordinary shares to Sponsor (1) |
— | — | — | |||||||||||||||||||||||||
| Net loss |
— | — | — | — | — | ( |
) | ( |
) | |||||||||||||||||||
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||
| Balance at March 31, 2021 |
$ |
$ |
$ |
$ |
( |
) |
$ |
|||||||||||||||||||||
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||
(1) |
Includes up to |
Three Months Ended March 31, 2022 |
For the period from February 3, 2021 (inception) through March 31, 2021 |
|||||||
| Cash Flows from Operating Activities: |
||||||||
| Net loss |
$ | ( |
) | $ | ( |
) | ||
| Adjustments to reconcile net loss to net cash used in operating activities: |
||||||||
| Payment of formation and operating costs through due to related party |
||||||||
| Payment of formation and operating costs through promissory note - related party |
||||||||
| Loss on sale of Private Placement Warrants |
||||||||
| Realized gain on investments held in Trust Account |
( |
) | ||||||
| Changes in operating assets and liabilities: |
||||||||
| Prepaid expenses |
||||||||
| Accounts payable |
( |
) | ||||||
| Accrued expenses |
||||||||
| Accrued expenses - related party |
||||||||
| |
|
|
|
|||||
| Net cash used in operating activities |
( |
) |
||||||
| |
|
|
|
|||||
| Cash Flows from Investing Activities: |
||||||||
| Cash deposited in Trust Account |
( |
) | ||||||
| |
|
|
|
|||||
| Net cash used in investing activities |
( |
) |
||||||
| |
|
|
|
|||||
| Cash Flows from Financing Activities: |
||||||||
| Proceeds from Initial Public Offering, net of underwriting discount paid |
||||||||
| Proceeds from sale of Private Placement Warrants |
||||||||
| |
|
|
|
|||||
| Net cash provided by financing activities |
||||||||
| |
|
|
|
|||||
| Net Change in Cash |
( |
) |
||||||
| Cash - Beginning of period |
||||||||
| |
|
|
|
|||||
| Cash - End of period |
$ |
$ |
||||||
| |
|
|
|
|||||
| Non-cash investing and financing activities: |
||||||||
| Deferred offering costs paid by Sponsor in exchange for issuance of Class B ordinary shares |
$ | $ | ||||||
| |
|
|
|
|||||
| Deferred offering costs included in accrued offering costs |
$ | $ | ||||||
| |
|
|
|
|||||
| Deferred offering costs included in due to related party |
$ | $ | ||||||
| |
|
|
|
|||||
| Accretion of Class A ordinary shares subject to redemption to redemption value |
$ | $ | ||||||
| |
|
|
|
|||||
| Deferred underwriting fee payable |
$ | $ | ||||||
| |
|
|
|
|||||
| Forfeiture of Class B ordinary shares by Sponsor |
$ | $ | ||||||
| |
|
|
|
|||||
March 31, 2022 |
December 31, 2021 |
|||||||
| Gross proceeds |
$ | $ | ||||||
| Less: |
||||||||
| Proceeds allocated to Public Warrants |
( |
) | ( |
) | ||||
| Issuance costs allocated to Class A ordinary shares |
( |
) | ( |
) | ||||
| Plus: |
||||||||
| Accretion of carrying value to redemption value |
||||||||
| |
|
|
|
|||||
| Class A ordinary shares subject to possible redemption |
$ |
$ |
||||||
| |
|
|
|
|||||
Three Months Ended March 31, 2022 |
For the Period From February 3, 2021 (Inception) Through March 31, 2021 |
|||||||||||||||
Class A |
Class B |
Class A |
Class B |
|||||||||||||
| Basic and diluted net loss per share: |
||||||||||||||||
| Numerator: |
||||||||||||||||
| Net loss |
$ | ( |
) | $ | ( |
) | $ | $ | ( |
) | ||||||
| |
|
|
|
|
|
|
|
|||||||||
| Denominator: |
||||||||||||||||
| Basic and diluted weighted average ordinary shares outstanding |
||||||||||||||||
| Basic and diluted net loss per ordinary share |
$ | ( |
) | $ | ( |
) | $ | $ | ( |
) | ||||||
| • | at any time after the warrants become exercisable; |
| • | upon a minimum of |
| • | if, and only if, the reported last sale price of the Class A ordinary shares equals or exceeds $ |
| • | if, and only if, there is a current registration statement in effect with respect to the Class A ordinary shares underlying such warrants. |
| Description |
Amount at Fair Value |
Level 1 |
Level 2 |
Level 3 |
||||||||||||
| March 31, 2022 |
||||||||||||||||
| Assets |
||||||||||||||||
| Investments held in Trust Account: |
||||||||||||||||
| U.S. Treasury Securities Money Market Funds |
$ | $ | $ | $ | ||||||||||||
| December 31, 202 1 |
||||||||||||||||
| Assets |
||||||||||||||||
| Investments held in Trust Account: |
||||||||||||||||
| U.S. Treasury Securities Money Market Funds |
$ | $ | $ | $ | ||||||||||||
| * | Filed herewith. |
| ** | Furnished herewith. |
| (1) | Incorporated by reference to the registrant’s Current Report on Form 8-K, filed with the SEC on December 20, 2021. |
SWIFTMERGE ACQUISITION CORP. | ||||||
| Date: May 18, 2022 | By: | /s/ John Bremner | ||||
| Name: | John Bremner | |||||
| Title: | Chief Executive Officer | |||||
SWIFTMERGE ACQUISITION CORP. | ||||||
| Date: May 18, 2022 | By: | /s/ Christopher J. Munyan | ||||
| Name: | Christopher J. Munyan | |||||
| Title: | Chief Financial Officer | |||||
No information found
* THE VALUE IS THE MARKET VALUE AS OF THE LAST DAY OF THE QUARTER FOR WHICH THE 13F WAS FILED.
| FUND | NUMBER OF SHARES | VALUE ($) | PUT OR CALL |
|---|
| DIRECTORS | AGE | BIO | OTHER DIRECTOR MEMBERSHIPS |
|---|
No information found
No Customers Found
No Suppliers Found
Price
Yield
| Owner | Position | Direct Shares | Indirect Shares |
|---|